Rokit Healthcare, a pioneering firm in AI-driven personalized longevity platforms, is set to unveil two cutting-edge anti-aging compounds this February. These products, designed to improve cognition and extend lifespan, will be distributed through the company’s extensive global network in 48 countries.
Leveraging its expertise in commercializing NMN-based cellular rejuvenation agents, Rokit Healthcare has developed Cell-Neuron, an innovative pipeline targeting both diabetes and mild cognitive impairment. Additionally, they’ve created a novel anti-aging formula focused on restoring the telomere microenvironment. The company has secured patents for these groundbreaking mechanisms and plans to introduce them to the global market by February.
Rokit Healthcare’s strategy is informed by the Type 3 Diabetes hypothesis, which posits a strong correlation between Alzheimer’s disease and brain insulin resistance. Recognizing that diabetics face twice the risk of dementia compared to the general population, the company aims to simultaneously address the global diabetes and dementia markets, valued at approximately 127.5 billion USD.
To establish a foothold in the U.S. market, Rokit Healthcare has initiated a global preclinical study on Cell-Neuron in partnership with the University of Nevada, Reno School of Medicine. This research, scheduled to continue until 2026, will investigate key biological mechanisms, including the regulation of glucose metabolism, the activation of NGF-TRKA signaling, and the reduction of neuroinflammation and oxidative stress. These findings will inform the company’s long-term strategy, including publication in high-impact journals and pursuing global licensing agreements.
The company’s innovative approach to telomere health departs from conventional lengthening techniques, instead focusing on revitalizing the telomere microenvironment. This strategy aligns with the Slow Aging concept, which aims to gently modulate the aging process.
The product, scheduled for U.S. launch in February, is built on three core principles: enhancing the microvascular environment, rebuilding extracellular matrix (ECM) support structures, and recalibrating inflammatory microenvironments.
Through AI-driven personalized design, the product aims to slow natural telomere shortening, preserve stem cell function, and reduce cancer risk by avoiding artificial genetic alterations.
A Rokit Healthcare spokesperson said its research on mild cognitive impairment had already yielded promising results in domestic trials, and described the collaboration with UNR as a pivotal moment in establishing global standards for addressing diabetic cognitive impairment, an area that remains largely unexplored.
They added that the company’s vision went beyond merely reversing aging, explaining that it was using AI to engineer optimal tissue environments that inherently resist aging, allowing cells to maintain their youthful state. They said this formed the cornerstone of Rokit Healthcare’s anti-aging platform, and added that with commercialization, the company was poised to revolutionize the field of AI-driven anti-aging solutions.